In
The News

In The News

Effects of ALT‑801, a GLP‑1 and glucagon receptor dual agonist, in a translational mouse model of non‑alcoholic steatohepatitis
April 23, 2022
Source
Scientific Reports
Potential New Obesity Drug Heads to Phase II Trials
January 31, 2022
Source
BioSpace
 

Investor Contact

Richard Eisenstadt
Chief Financial Officer

Email: reisenstadt@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe